FULCRUM THERAPEUTICS INC (FULC)

Company Profile

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2019-07-18. The firm is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The firm has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.

Company Info

FULCRUM THERAPEUTICS INC

26 Landsdowne Street

Cambridge MASSACHUSETTS 02139

P: 16176518851

CEO: Robert J. Gould

Employees: 76

Website: https://www.fulcrumtx.com/